Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Needle Free Diabetes Care Market Trends

ID: MRFR/MED/0407-HCR
110 Pages
Rahul Gotadki
March 2026

Needle Free Diabetes Care Market Research Report, By Devices Types (Treatment Devices And Diagnostic Devices), Treatment (Oral Insulin, Inhaled Insulin, Insulin Patch, Others), Application (Insulin Delivery And Other), End Users (Diagnostic Centers, Hospitals & Clinics And Other) - Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Needle free diabetes care Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Needle free diabetes care Market

The needle-free diabetes treatment industry is changing due to diabetes management changes. This novel strategy aims to reduce the discomfort of standard insulin delivery procedures for patients. Non-harmful technologies are becoming more popular. Inhalable insulin and skin patches may replace needle-based injections, making diabetes life easier emotionally and physically. The reason for this change was to meet the growing need for diabetes treatments that are less invasive and easier to use. Insulin that you breathe in is the most popular needle-free way to treat diabetes. Inhalable insulin delivery devices are more dependable and efficient now that technology has improved. This trend makes self-administration of insulin easier and helps diabetics regulate their blood sugar. Transdermal patches are another exciting needle-free diabetic therapy. If you put these patches to your skin, the epidermis will release insulin, eliminating the need for injections. For more accurate and consistent insulin administration, patch technologies are being developed. It will provide patients a more private and pleasant choice. Market trends indicate that needle-free diabetes management devices are becoming more patient-centered and easier to use. Medical gadget manufacturers spend a lot on ergonomic and user-friendly designs. This ensures that diabetics may utilize these gadgets easily in their daily lives. This focus on utility aims to improve patient satisfaction and collaboration. As more people learn about needle-free diabetes treatments, patients and doctors are accepting them. Awareness and education campaigns are essential to dispelling many myths regarding these new technology. This will make people use these technologies more. Intelligent technology in needle-free diabetes treatment options is exciting. Insulin pens, pumps, and patches with connection and data monitoring tools provide real-time glucose monitoring. Track your glucose levels with these. This approach is growing increasingly popular as healthcare becomes more personalized and data-driven. The needle-free diabetes treatment business is growing in developing countries. This is because more people are acquiring diabetes and middle-class people can afford better health care. Due to this trend, diabetes care is changing worldwide to provide more people new treatment options. Legislation and treatment standardization are transforming needle-free diabetes care. Governments and other governing agencies are collaborating with corporations to establish laws for these new technologies to assure safety and efficacy. Each form of aid makes industry growth easier.

Pharmaceutical, technology, and healthcare companies are partnering more as the needle-free diabetes treatment market grows. These collaborations aim to harness the best features of each industry to speed up discovery, improve product development, and improve needle-free diabetes treatment choices.

Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the projected market valuation of the Needle-Free Diabetes Care Market by 2035?

The projected market valuation for the Needle-Free Diabetes Care Market is expected to reach 29.79 USD Billion by 2035.

What was the market valuation of the Needle-Free Diabetes Care Market in 2024?

The overall market valuation was 13.12 USD Billion in 2024.

What is the expected CAGR for the Needle-Free Diabetes Care Market during the forecast period 2025 - 2035?

The expected CAGR for the Needle-Free Diabetes Care Market during the forecast period 2025 - 2035 is 7.74%.

Which companies are considered key players in the Needle-Free Diabetes Care Market?

Key players in the Needle-Free Diabetes Care Market include Insulet Corporation, Medtronic, Novo Nordisk, and others.

What are the projected values for Continuous Glucose Monitoring devices by 2035?

The projected value for Continuous Glucose Monitoring devices is expected to reach 7.0 USD Billion by 2035.

How much is the Insulin Patch segment expected to grow by 2035?

The Insulin Patch segment is projected to grow to 5.5 USD Billion by 2035.

What is the expected market size for Insulin Delivery applications by 2035?

The expected market size for Insulin Delivery applications is anticipated to reach 18.0 USD Billion by 2035.

What is the projected market size for hospitals and clinics as end-users by 2035?

The projected market size for hospitals and clinics as end-users is expected to reach 12.0 USD Billion by 2035.

What is the expected growth for Instant Glucose Monitoring devices by 2035?

The expected growth for Instant Glucose Monitoring devices is projected to reach 4.5 USD Billion by 2035.

What are the anticipated values for the Others segment in the Treatment category by 2035?

The anticipated value for the Others segment in the Treatment category is expected to reach 13.79 USD Billion by 2035.

Market Summary

As per Market Research Future analysis, the Needle Free Diabetes Care Market Size was estimated at 13.12 USD Billion in 2024. The Needle Free Diabetes Care industry is projected to grow from 14.14 USD Billion in 2025 to 29.79 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.74% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Needle Free Diabetes Care Market is poised for substantial growth driven by technological advancements and increasing patient-centric approaches.

  • Technological advancements in delivery systems are revolutionizing the needle-free diabetes care landscape. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in this sector. The Continuous Glucose Monitoring segment leads the market, whereas the Insulin Pen segment is witnessing rapid growth. Rising prevalence of diabetes and government initiatives are key drivers propelling the adoption of needle-free devices.

Market Size & Forecast

2024 Market Size 13.12 (USD Billion)
2035 Market Size 29.79 (USD Billion)
CAGR (2025 - 2035) 7.74%
Largest Regional Market Share in 2024 North America

Major Players

Insulet Corporation (US), Medtronic (US), Novo Nordisk (DK), Becton Dickinson and Company (US), AstraZeneca (GB), Eli Lilly and Company (US), Sanofi (FR), Roche (CH), Abbott Laboratories (US)

Market Trends

The Needle-Free Diabetes Care Market is currently experiencing a transformative phase, driven by advancements in technology and a growing emphasis on patient comfort. Innovations in drug delivery systems, such as microneedles and jet injectors, are gaining traction as they offer painless alternatives to traditional methods. This shift is not merely a response to consumer demand; it reflects a broader trend towards minimizing discomfort and enhancing the overall experience for individuals managing diabetes. Furthermore, the increasing prevalence of diabetes worldwide necessitates the development of more efficient and user-friendly solutions, which the Needle-Free Diabetes Care Market appears well-positioned to address. In addition to technological advancements, the market is influenced by rising awareness regarding diabetes management and the importance of adherence to treatment regimens. Healthcare providers are increasingly advocating for needle-free options, which may lead to improved patient compliance. Moreover, the integration of digital health solutions, such as mobile applications for monitoring and managing diabetes, complements the needle-free approach, creating a holistic ecosystem for diabetes care. As the Needle-Free Diabetes Care Market evolves, it is likely to witness further innovations that prioritize patient-centric solutions, ultimately aiming to enhance quality of life for those affected by diabetes.

Technological Advancements in Delivery Systems

The Needle-Free Diabetes Care Market is witnessing a surge in innovative delivery systems that prioritize patient comfort. Technologies such as microneedles and jet injectors are emerging as viable alternatives to traditional methods, potentially revolutionizing how insulin and other medications are administered. These advancements not only reduce pain but also enhance the overall user experience, making diabetes management more accessible.

Increased Focus on Patient Compliance

There is a growing emphasis on improving patient compliance within the Needle-Free Diabetes Care Market. Healthcare professionals are advocating for needle-free solutions, which may lead to better adherence to treatment regimens. This focus on compliance is crucial, as it directly impacts health outcomes and the effectiveness of diabetes management strategies.

Integration of Digital Health Solutions

The integration of digital health technologies is becoming increasingly relevant in the Needle-Free Diabetes Care Market. Mobile applications and telehealth services are complementing needle-free options, providing users with tools for monitoring and managing their condition. This synergy between technology and care solutions is likely to enhance the overall effectiveness of diabetes management.

Needle free diabetes care Market Market Drivers

Rising Prevalence of Diabetes

The Needle Free Diabetes Care Market is significantly influenced by the rising prevalence of diabetes worldwide. As the number of individuals diagnosed with diabetes continues to increase, the demand for effective and less invasive treatment options is also on the rise. Current statistics indicate that approximately 463 million adults are living with diabetes, a figure that is expected to reach 700 million by 2045. This alarming trend underscores the urgent need for innovative solutions, such as needle-free delivery systems, which can facilitate better management of the condition. The growing awareness of diabetes complications further propels the market, as patients seek alternatives that minimize discomfort while ensuring effective treatment.

Patient-Centric Healthcare Trends

The Needle Free Diabetes Care Market is benefiting from a shift towards patient-centric healthcare models. This trend emphasizes the importance of patient comfort and satisfaction in treatment protocols. As healthcare providers increasingly prioritize the patient experience, needle-free options are becoming more attractive. The convenience of these systems, which often allow for self-administration, aligns with the growing demand for personalized healthcare solutions. Furthermore, studies suggest that patient compliance improves when treatment methods are less invasive. This shift not only enhances the quality of care but also drives market growth, as more patients opt for needle-free alternatives that align with their lifestyle and preferences.

Government Initiatives and Funding

The Needle Free Diabetes Care Market is also being propelled by various government initiatives aimed at improving diabetes care. Many governments are investing in research and development to promote innovative healthcare solutions, including needle-free delivery systems. Funding programs and grants are increasingly available to support the development of technologies that enhance patient care. For instance, initiatives aimed at reducing healthcare costs and improving patient outcomes are likely to encourage the adoption of needle-free options. This supportive regulatory environment not only fosters innovation but also creates a favorable market landscape for companies specializing in needle-free diabetes care solutions.

Integration of Wearable Technology

The Needle Free Diabetes Care Market is poised for growth due to the integration of wearable technology in diabetes management. Wearable devices that monitor glucose levels continuously are becoming increasingly popular, allowing for real-time data collection and analysis. This integration facilitates the development of needle-free delivery systems that can be synchronized with these devices, providing a seamless experience for users. The market for wearable technology in diabetes care is expected to reach USD 27 billion by 2026, indicating a robust demand for innovative solutions. As patients seek more efficient ways to manage their condition, the combination of wearables and needle-free systems presents a compelling opportunity for market expansion.

Technological Innovations in Needle-Free Devices

The Needle Free Diabetes Care Market is experiencing a surge in technological innovations that enhance the efficacy and user-friendliness of diabetes management devices. Recent advancements in microneedle technology and jet injectors have made it possible to deliver insulin and other medications without the discomfort associated with traditional needles. These innovations not only improve patient experience but also increase adherence to treatment regimens. According to recent estimates, the market for needle-free delivery systems is projected to grow at a compound annual growth rate of approximately 8% over the next five years. This growth is indicative of a broader trend towards minimizing pain and anxiety associated with diabetes care, thereby making needle-free options more appealing to patients.

Market Segment Insights

By Device Types: Continuous Glucose Monitoring (Largest) vs. Insulin Pen (Fastest-Growing)

The Needle-Free Diabetes Care Market is predominantly segmented into various device types, with Continuous Glucose Monitoring (CGM) leading the charge as the market's largest segment. Diagnostic devices and instant glucose monitoring play crucial roles in patient management, contributing significantly to overall market dynamics. Additionally, treatment devices such as insulin pens and patches are also noteworthy, as they address different patient needs and preferences, further diversifying the market landscape.

Continuous Glucose Monitoring (Dominant) vs. Insulin Pen (Emerging)

Continuous Glucose Monitoring (CGM) systems are at the forefront of diabetes management, providing real-time glucose levels and historical trends to users. These devices enhance patient autonomy and facilitate timely interventions, making them highly appealing in the market. Conversely, insulin pens have emerged as an increasingly popular choice for treatment, especially among individuals seeking ease of use and discreet delivery methods. As new technologies evolve, such as <a href="https://www.marketresearchfuture.com/reports/smart-insulin-pens-market-6789" target="_blank" title="smart insulin pens">smart insulin pens</a> with connectivity features, their adoption rates are likely to rise, indicating their status as an emerging category within the market.

By Treatment: Insulin Patch (Largest) vs. Inhaled Insulin (Fastest-Growing)

The Needle-Free Diabetes Care Market comprises several key treatment options, namely insulin patches, inhaled insulin, oral insulin, and other methods. Among these, insulin patches currently hold the largest market share due to their convenience, ease of use, and non-invasive nature. Inhaled insulin, on the other hand, is gaining rapid popularity, attracting attention for its potential to revolutionize insulin delivery by providing faster absorption compared to traditional methods. Oral insulin and other methods follow, marking notable efforts to enhance patient adherence and optimize diabetes management.

Insulin Patch (Dominant) vs. Inhaled Insulin (Emerging)

The insulin patch has established itself as a dominant force within the Needle-Free Diabetes Care Market, primarily due to its user-friendly application and consistent dosage delivery, making it appealing to a broad range of diabetic patients. This segment is characterized by advancements in technology that enhance skin adhesion and drug stability, contributing to user satisfaction. On the contrary, inhaled insulin is regarded as an emerging solution, emphasizing speed and convenience. It targets patients who may have difficulties with traditional injections or whose lifestyle demands a more adaptable insulin delivery option. As clinical trials yield encouraging results, inhaled insulin is positioned to expand significantly, striking a balance between efficacy and patient preference.

By Application: Insulin Delivery (Largest) vs. Others (Fastest-Growing)

The Needle-Free Diabetes Care Market is primarily dominated by the Insulin Delivery segment, which has established itself as the largest category due to the increasing prevalence of diabetes and the rising demand for less invasive treatment alternatives. This segment captures a significant share of the overall market, as patients increasingly prefer needle-free systems that offer convenience and pain reduction during insulin administration. In contrast, the 'Others' segment, which includes various alternative applications and delivery methods, is rapidly gaining traction as innovative solutions emerge, catering to a broader range of diabetes care options.

Insulin Delivery (Dominant) vs. Others (Emerging)

The Insulin Delivery segment stands out as the dominant player within the Needle-Free Diabetes Care Market, as it focuses on providing efficient and user-friendly solutions for insulin administration without needles. This category addresses critical patient needs by minimizing pain and anxiety associated with traditional injection methods. The emergence of advanced technologies in insulin delivery systems has significantly contributed to its strong market position. Conversely, the 'Others' segment is recognized as an emerging category that encompasses a diverse range of newer technologies aimed at enhancing diabetes management, such as smart pens and integrated delivery systems. The evolving landscape of diabetes care is fueling growth in this segment as more patients look for innovative solutions that enhance their treatment experiences.

By End-user: Hospitals & Clinics (Largest) vs. Diagnostic Centres (Fastest-Growing)

In the Needle-Free Diabetes Care Market, the end-user segment is distributed primarily among hospitals &amp; clinics, diagnostic centres, and other healthcare providers. Currently, hospitals and clinics hold the largest share due to their extensive patient base and continuous demand for efficient diabetes management solutions. This dominance is reinforced by their ability to invest in advanced technology and treatment methods, fulfilling the needs of diabetic patients effectively. Meanwhile, diagnostic centres are increasingly capturing market attention, driven by rising awareness and demand for non-invasive diabetes screening methods.

Hospitals &amp; Clinics (Dominant) vs. Diagnostic Centres (Emerging)

The hospitals &amp; clinics segment is characterized by a significant volume of diabetes management procedures, making it the dominant end-user in the Needle-Free Diabetes Care Market. These facilities benefit from strong patient inflow and a diverse range of medical services, including preventive care and chronic disease management. Additionally, the integration of needle-free devices enhances patient comfort and compliance, further solidifying their position in the market. On the other hand, diagnostic centres represent an emerging segment focusing on innovative testing methods. As awareness surrounding diabetes increases, these centres are leveraging advanced technologies to provide rapid and pain-free testing solutions, thereby attracting a growing clientele who prefer convenience without compromising accuracy.

Get more detailed insights about Needle Free Diabetes Care Market Research Report- Forecast To 2035

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for needle-free diabetes care, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high diabetes prevalence, and increasing demand for non-invasive treatment options. Regulatory support from agencies like the FDA has accelerated the approval of innovative devices, driving market growth. The rising awareness of diabetes management and technological advancements further fuel demand. The United States is the primary contributor, with key players like Insulet Corporation, Medtronic, and Abbott Laboratories leading the market. The competitive landscape is characterized by continuous innovation and strategic partnerships among these companies. Canada also plays a significant role, focusing on improving diabetes care through needle-free technologies, enhancing patient compliance and comfort.

Europe : Emerging Market with Growth Potential

Europe is witnessing significant growth in the needle-free diabetes care market, accounting for approximately 30% of the global share. The region's growth is driven by increasing diabetes prevalence, supportive healthcare policies, and a strong emphasis on patient-centric care. Countries like Germany and France are leading the charge, with regulatory bodies promoting innovative healthcare solutions to improve patient outcomes. The European Medicines Agency (EMA) has been instrumental in facilitating the approval of new technologies. Germany stands out as a key market, with major players like Novo Nordisk and Sanofi actively investing in needle-free solutions. The competitive landscape is marked by collaborations between pharmaceutical companies and technology firms, enhancing product offerings. The focus on reducing the burden of diabetes management is driving demand for needle-free devices, making Europe a vital region for market expansion.

Asia-Pacific : Rapid Growth in Emerging Economies

Asia-Pacific is rapidly emerging as a significant player in the needle-free diabetes care market, holding about 20% of the global share. The region's growth is fueled by rising diabetes rates, increasing healthcare expenditure, and a growing awareness of non-invasive treatment options. Countries like China and India are at the forefront, with government initiatives aimed at improving diabetes management and healthcare access. Regulatory frameworks are evolving to support innovative medical devices, further driving market growth. China is the largest market in the region, with a strong presence of local and international players. Companies like Becton Dickinson and Medtronic are expanding their operations to cater to the growing demand. The competitive landscape is characterized by a mix of established firms and emerging startups, focusing on technological advancements and affordability to enhance patient compliance and care.

Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa region is gradually recognizing the potential of needle-free diabetes care, currently holding about 5% of the global market share. The growth is driven by increasing diabetes prevalence, rising healthcare investments, and a shift towards innovative treatment solutions. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at improving healthcare infrastructure and access to diabetes care. Regulatory bodies are beginning to support the introduction of advanced medical technologies. South Africa is a key market, with a growing number of healthcare providers adopting needle-free solutions to enhance patient comfort. The competitive landscape is still developing, with both local and international players exploring opportunities in this emerging market. The focus on improving diabetes management and patient outcomes is expected to drive future growth in the region.

Key Players and Competitive Insights

The Needle-Free Diabetes Care Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for patient-friendly solutions. Key players such as Insulet Corporation (US), Medtronic (US), and Novo Nordisk (DK) are at the forefront, each adopting distinct strategies to enhance their market positioning. Insulet Corporation (US) focuses on innovation through its Omnipod system, which offers a tubeless insulin delivery solution, while Medtronic (US) emphasizes digital transformation with its integrated diabetes management systems. Novo Nordisk (DK), on the other hand, is leveraging partnerships to expand its product offerings and reach, particularly in emerging markets. Collectively, these strategies contribute to a competitive environment that is increasingly centered around patient-centric solutions and technological integration.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set the pace for innovation and operational excellence. This competitive structure allows for a diverse range of products and services, catering to varying patient needs and preferences.

In August 2025, Insulet Corporation (US) announced a strategic partnership with a leading technology firm to enhance its data analytics capabilities. This collaboration aims to improve patient outcomes by providing real-time insights into insulin delivery and glucose monitoring. The strategic importance of this move lies in its potential to position Insulet as a leader in personalized diabetes management, leveraging data to drive better health outcomes.

In September 2025, Medtronic (US) launched a new version of its insulin pump that integrates advanced AI algorithms for predictive analytics. This innovation is expected to significantly improve the user experience by anticipating insulin needs based on real-time data. The introduction of AI into diabetes care reflects a broader trend towards digitalization, indicating Medtronic's commitment to staying ahead in a competitive market.

In July 2025, Novo Nordisk (DK) expanded its product line by introducing a needle-free delivery system for its GLP-1 receptor agonists. This strategic move not only enhances patient compliance but also aligns with the growing demand for less invasive treatment options. By diversifying its offerings, Novo Nordisk is likely to strengthen its market position and appeal to a broader patient demographic.

As of October 2025, current competitive trends in the Needle-Free Diabetes Care Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of developing unique, patient-centric solutions that not only meet regulatory standards but also enhance the overall patient experience.

Key Companies in the Needle free diabetes care Market include

Industry Developments

Echo Therapeutics has developed a needle-free diabetic tester that uses a patch instead of a needle poke. The transdermal biosensor examines the blood analytes through the skin with blood drawn from the body.

DiaMonTech launched its diabetes monitor D-Base that measures blood glucose levels by passing an infrared ray through the skin. The levels are evaluated by monitoring the temperature changes on the skin.

Portal Instruments launched its jet-injection device that injects insulin into the skin through a ‘hair-thin’ stream.

Future Outlook

Needle free diabetes care Market Future Outlook

The Needle-Free Diabetes Care Market is projected to grow at a 7.74% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and demand for patient-friendly solutions.

New opportunities lie in:

  • <p>Development of smart needle-free devices with integrated data analytics Expansion into emerging markets with tailored product offerings Partnerships with healthcare providers for integrated diabetes management solutions</p>

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in diabetes care innovation.

Market Segmentation

Needle free diabetes care Market End-user Outlook

  • Hospitals & clinics
  • Diagnostic centres
  • Others

Needle free diabetes care Market Treatment Outlook

  • Insulin patch
  • Inhaled insulin
  • Oral insulin
  • Others

Needle free diabetes care Market Application Outlook

  • Insulin delivery
  • Others

Needle free diabetes care Market Device Types Outlook

  • Diagnostic devices
  • Instant glucose monitoring
  • Continuous glucose monitoring
  • Treatment devices
  • Insulin pen
  • Insulin patch
  • Insulin pump
  • Insulin inhaler
  • Insulin jet injector

Report Scope

MARKET SIZE 2024 13.12(USD Billion)
MARKET SIZE 2025 14.14(USD Billion)
MARKET SIZE 2035 29.79(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.74% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Insulet Corporation (US), Medtronic (US), Novo Nordisk (DK), Becton Dickinson and Company (US), AstraZeneca (GB), Eli Lilly and Company (US), Sanofi (FR), Roche (CH), Abbott Laboratories (US)
Segments Covered Devices Types
Key Market Opportunities Advancements in technology enable innovative solutions for pain-free glucose monitoring in the Needle-Free Diabetes Care Market.
Key Market Dynamics Technological advancements drive adoption of needle-free devices, enhancing patient compliance and reshaping diabetes management strategies.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Needle-Free Diabetes Care Market by 2035?

The projected market valuation for the Needle-Free Diabetes Care Market is expected to reach 29.79 USD Billion by 2035.

What was the market valuation of the Needle-Free Diabetes Care Market in 2024?

The overall market valuation was 13.12 USD Billion in 2024.

What is the expected CAGR for the Needle-Free Diabetes Care Market during the forecast period 2025 - 2035?

The expected CAGR for the Needle-Free Diabetes Care Market during the forecast period 2025 - 2035 is 7.74%.

Which companies are considered key players in the Needle-Free Diabetes Care Market?

Key players in the Needle-Free Diabetes Care Market include Insulet Corporation, Medtronic, Novo Nordisk, and others.

What are the projected values for Continuous Glucose Monitoring devices by 2035?

The projected value for Continuous Glucose Monitoring devices is expected to reach 7.0 USD Billion by 2035.

How much is the Insulin Patch segment expected to grow by 2035?

The Insulin Patch segment is projected to grow to 5.5 USD Billion by 2035.

What is the expected market size for Insulin Delivery applications by 2035?

The expected market size for Insulin Delivery applications is anticipated to reach 18.0 USD Billion by 2035.

What is the projected market size for hospitals and clinics as end-users by 2035?

The projected market size for hospitals and clinics as end-users is expected to reach 12.0 USD Billion by 2035.

What is the expected growth for Instant Glucose Monitoring devices by 2035?

The expected growth for Instant Glucose Monitoring devices is projected to reach 4.5 USD Billion by 2035.

What are the anticipated values for the Others segment in the Treatment category by 2035?

The anticipated value for the Others segment in the Treatment category is expected to reach 13.79 USD Billion by 2035.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Device Types (USD Billion)
    2. | | 4.1.1 Diagnostic devices
    3. | | 4.1.2 Instant glucose monitoring
    4. | | 4.1.3 Continuous glucose monitoring
    5. | | 4.1.4 Treatment devices
    6. | | 4.1.5 Insulin pen
    7. | | 4.1.6 Insulin patch
    8. | | 4.1.7 Insulin pump
    9. | | 4.1.8 Insulin inhaler
    10. | | 4.1.9 Insulin jet injector
    11. | 4.2 Healthcare, BY Treatment (USD Billion)
    12. | | 4.2.1 Insulin patch
    13. | | 4.2.2 Inhaled insulin
    14. | | 4.2.3 Oral insulin
    15. | | 4.2.4 Others
    16. | 4.3 Healthcare, BY Application (USD Billion)
    17. | | 4.3.1 Insulin delivery
    18. | | 4.3.2 Others
    19. | 4.4 Healthcare, BY End-user (USD Billion)
    20. | | 4.4.1 Hospitals & clinics
    21. | | 4.4.2 Diagnostic centres
    22. | | 4.4.3 Others
    23. | 4.5 Healthcare, BY Region (USD Billion)
    24. | | 4.5.1 North America
    25. | | | 4.5.1.1 US
    26. | | | 4.5.1.2 Canada
    27. | | 4.5.2 Europe
    28. | | | 4.5.2.1 Germany
    29. | | | 4.5.2.2 UK
    30. | | | 4.5.2.3 France
    31. | | | 4.5.2.4 Russia
    32. | | | 4.5.2.5 Italy
    33. | | | 4.5.2.6 Spain
    34. | | | 4.5.2.7 Rest of Europe
    35. | | 4.5.3 APAC
    36. | | | 4.5.3.1 China
    37. | | | 4.5.3.2 India
    38. | | | 4.5.3.3 Japan
    39. | | | 4.5.3.4 South Korea
    40. | | | 4.5.3.5 Malaysia
    41. | | | 4.5.3.6 Thailand
    42. | | | 4.5.3.7 Indonesia
    43. | | | 4.5.3.8 Rest of APAC
    44. | | 4.5.4 South America
    45. | | | 4.5.4.1 Brazil
    46. | | | 4.5.4.2 Mexico
    47. | | | 4.5.4.3 Argentina
    48. | | | 4.5.4.4 Rest of South America
    49. | | 4.5.5 MEA
    50. | | | 4.5.5.1 GCC Countries
    51. | | | 4.5.5.2 South Africa
    52. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Insulet Corporation (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Medtronic (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Novo Nordisk (DK)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Becton Dickinson and Company (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 AstraZeneca (GB)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Eli Lilly and Company (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Sanofi (FR)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Roche (CH)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Abbott Laboratories (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY DEVICE TYPES
    4. | 6.4 US MARKET ANALYSIS BY TREATMENT
    5. | 6.5 US MARKET ANALYSIS BY APPLICATION
    6. | 6.6 US MARKET ANALYSIS BY END-USER
    7. | 6.7 CANADA MARKET ANALYSIS BY DEVICE TYPES
    8. | 6.8 CANADA MARKET ANALYSIS BY TREATMENT
    9. | 6.9 CANADA MARKET ANALYSIS BY APPLICATION
    10. | 6.10 CANADA MARKET ANALYSIS BY END-USER
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY DEVICE TYPES
    13. | 6.13 GERMANY MARKET ANALYSIS BY TREATMENT
    14. | 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
    15. | 6.15 GERMANY MARKET ANALYSIS BY END-USER
    16. | 6.16 UK MARKET ANALYSIS BY DEVICE TYPES
    17. | 6.17 UK MARKET ANALYSIS BY TREATMENT
    18. | 6.18 UK MARKET ANALYSIS BY APPLICATION
    19. | 6.19 UK MARKET ANALYSIS BY END-USER
    20. | 6.20 FRANCE MARKET ANALYSIS BY DEVICE TYPES
    21. | 6.21 FRANCE MARKET ANALYSIS BY TREATMENT
    22. | 6.22 FRANCE MARKET ANALYSIS BY APPLICATION
    23. | 6.23 FRANCE MARKET ANALYSIS BY END-USER
    24. | 6.24 RUSSIA MARKET ANALYSIS BY DEVICE TYPES
    25. | 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT
    26. | 6.26 RUSSIA MARKET ANALYSIS BY APPLICATION
    27. | 6.27 RUSSIA MARKET ANALYSIS BY END-USER
    28. | 6.28 ITALY MARKET ANALYSIS BY DEVICE TYPES
    29. | 6.29 ITALY MARKET ANALYSIS BY TREATMENT
    30. | 6.30 ITALY MARKET ANALYSIS BY APPLICATION
    31. | 6.31 ITALY MARKET ANALYSIS BY END-USER
    32. | 6.32 SPAIN MARKET ANALYSIS BY DEVICE TYPES
    33. | 6.33 SPAIN MARKET ANALYSIS BY TREATMENT
    34. | 6.34 SPAIN MARKET ANALYSIS BY APPLICATION
    35. | 6.35 SPAIN MARKET ANALYSIS BY END-USER
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY DEVICE TYPES
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY END-USER
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY DEVICE TYPES
    42. | 6.42 CHINA MARKET ANALYSIS BY TREATMENT
    43. | 6.43 CHINA MARKET ANALYSIS BY APPLICATION
    44. | 6.44 CHINA MARKET ANALYSIS BY END-USER
    45. | 6.45 INDIA MARKET ANALYSIS BY DEVICE TYPES
    46. | 6.46 INDIA MARKET ANALYSIS BY TREATMENT
    47. | 6.47 INDIA MARKET ANALYSIS BY APPLICATION
    48. | 6.48 INDIA MARKET ANALYSIS BY END-USER
    49. | 6.49 JAPAN MARKET ANALYSIS BY DEVICE TYPES
    50. | 6.50 JAPAN MARKET ANALYSIS BY TREATMENT
    51. | 6.51 JAPAN MARKET ANALYSIS BY APPLICATION
    52. | 6.52 JAPAN MARKET ANALYSIS BY END-USER
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY DEVICE TYPES
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY END-USER
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY DEVICE TYPES
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY END-USER
    61. | 6.61 THAILAND MARKET ANALYSIS BY DEVICE TYPES
    62. | 6.62 THAILAND MARKET ANALYSIS BY TREATMENT
    63. | 6.63 THAILAND MARKET ANALYSIS BY APPLICATION
    64. | 6.64 THAILAND MARKET ANALYSIS BY END-USER
    65. | 6.65 INDONESIA MARKET ANALYSIS BY DEVICE TYPES
    66. | 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT
    67. | 6.67 INDONESIA MARKET ANALYSIS BY APPLICATION
    68. | 6.68 INDONESIA MARKET ANALYSIS BY END-USER
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY DEVICE TYPES
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY END-USER
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY DEVICE TYPES
    75. | 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT
    76. | 6.76 BRAZIL MARKET ANALYSIS BY APPLICATION
    77. | 6.77 BRAZIL MARKET ANALYSIS BY END-USER
    78. | 6.78 MEXICO MARKET ANALYSIS BY DEVICE TYPES
    79. | 6.79 MEXICO MARKET ANALYSIS BY TREATMENT
    80. | 6.80 MEXICO MARKET ANALYSIS BY APPLICATION
    81. | 6.81 MEXICO MARKET ANALYSIS BY END-USER
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY DEVICE TYPES
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY END-USER
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DEVICE TYPES
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY DEVICE TYPES
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USER
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY DEVICE TYPES
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USER
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY DEVICE TYPES
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY END-USER
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY DEVICE TYPES, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY DEVICE TYPES, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY END-USER, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY TREATMENT, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY END-USER, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY TREATMENT, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY APPLICATION, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY END-USER, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY TREATMENT, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY APPLICATION, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY END-USER, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY TREATMENT, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY APPLICATION, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY END-USER, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY TREATMENT, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY APPLICATION, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY END-USER, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY TREATMENT, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY APPLICATION, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY END-USER, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY TREATMENT, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY APPLICATION, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY END-USER, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY TREATMENT, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY APPLICATION, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY END-USER, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY TREATMENT, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY APPLICATION, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY END-USER, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY TREATMENT, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY APPLICATION, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY END-USER, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY TREATMENT, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY APPLICATION, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY END-USER, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY TREATMENT, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY APPLICATION, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY END-USER, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY TREATMENT, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY APPLICATION, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY END-USER, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY TREATMENT, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY APPLICATION, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY END-USER, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY TREATMENT, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY APPLICATION, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY END-USER, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY TREATMENT, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY APPLICATION, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY END-USER, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY TREATMENT, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY APPLICATION, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY END-USER, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY TREATMENT, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY APPLICATION, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY END-USER, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY TREATMENT, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY APPLICATION, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY END-USER, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY TREATMENT, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY APPLICATION, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY END-USER, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY TREATMENT, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY APPLICATION, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY END-USER, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY TREATMENT, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY APPLICATION, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY END-USER, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY TREATMENT, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY APPLICATION, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY END-USER, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY TREATMENT, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY APPLICATION, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY END-USER, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY TREATMENT, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY APPLICATION, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY END-USER, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY TREATMENT, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY APPLICATION, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY END-USER, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY TREATMENT, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY APPLICATION, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY END-USER, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY TREATMENT, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY APPLICATION, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY END-USER, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY DEVICE TYPES, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY TREATMENT, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY APPLICATION, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY END-USER, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Device Types (USD Billion, 2025-2035)

  • Diagnostic devices
  • Instant glucose monitoring
  • Continuous glucose monitoring
  • Treatment devices
  • Insulin pen
  • Insulin patch
  • Insulin pump
  • Insulin inhaler
  • Insulin jet injector

Healthcare By Treatment (USD Billion, 2025-2035)

  • Insulin patch
  • Inhaled insulin
  • Oral insulin
  • Others

Healthcare By Application (USD Billion, 2025-2035)

  • Insulin delivery
  • Others

Healthcare By End-user (USD Billion, 2025-2035)

  • Hospitals & clinics
  • Diagnostic centres
  • Others
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓